Literature DB >> 28830679

Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aorta.

Brandi M Wynne1, Hicham Labazi2, Zidonia N Carneiro3, Rita C Tostes4, R Clinton Webb5.   

Abstract

Nitroglycerin (Gtn) is a treatment for cardiovascular patients due to its vasodilatory actions, but induces tolerance when given chronically. A proposed mechanism is the superoxide (O2-)-oxidative stress hypothesis, which suggests that Gtn increases O2- production. Nitric oxide (NO) exists in three different redox states; the protonated, reduced state, nitroxyl anion (HNO) is an emerging candidate in vascular regulation. HNO is resistant to scavenging and of particular interest in conditions where high levels of reactive oxygen species (ROS) exist. We hypothesize that treatment with Gtn will exacerbate endothelin 1 (ET-1) induced vascular dysfunction via an increase in ROS, while treatment with Angeli's Salt (AS), an HNO donor, will not. Aorta from mice were isolated and divided into four groups: vehicle, ET-1 [0.1μM, 1μM], ET-1+Gtn [Gtn 1μM] and ET-1+AS [AS 1μM]. Concentration response curves (CRCs) to acetylcholine (ACh) and phenylephrine (Phe) were performed. Aorta incubated with ET-1 (for 20-22h) exhibited a decreased relaxation response to ACh and an increase in Phe-mediated contraction. Aorta incubated with AS exhibited a reversal in ET-1 induced vascular and endothelial dysfunction. ET-1 increased ROS in aortic vascular smooth muscle cells (VSMCs), visualized by dihydroethidium (DHE) staining. AS incubated reduced this ROS generation, yet maintained with Gtn treatment. These data suggest that aorta incubated with the HNO donor, AS, can reverse ET-1 mediated vascular dysfunction, which may be through a decrease or prevention of ROS generation. We propose that HNO may be vasoprotective and that HNO donors studied as a therapeutic option where other organic nitrates are contraindicative.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angeli's Salt; Endothelin-1; HNO; Nitroglycerin; Vascular dysfunction

Mesh:

Substances:

Year:  2017        PMID: 28830679      PMCID: PMC5777347          DOI: 10.1016/j.ejphar.2017.08.024

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  58 in total

1.  Redox variants of NO (NO{middle dot} and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms.

Authors:  Joanne L Favaloro; Barbara K Kemp-Harper
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-27       Impact factor: 4.733

2.  The shy Angeli and his elusive creature: the HNO route to vasodilation.

Authors:  Nazareno Paolocci; David A Wink
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

3.  Endothelin-1 shifts the mediator of bradykinin-induced relaxation from NO to H2 O2 in resistance arteries from patients with cardiovascular disease.

Authors:  Thomas M Leurgans; Maria Bloksgaard; Jonathan R Brewer; Luis A Bagatolli; Maise H Fredgart; Kristoffer Rosenstand; Maria L Hansen; Lars M Rasmussen; Akhmadjon Irmukhamedov; Jo Gr De Mey
Journal:  Br J Pharmacol       Date:  2016-04-06       Impact factor: 8.739

4.  Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment.

Authors:  Eberhard Schulz; Nikolaus Tsilimingas; Ruth Rinze; Beate Reiter; Maria Wendt; Mathias Oelze; Silke Woelken-Weckmüller; Ulrich Walter; Hermann Reichenspurner; Thomas Meinertz; Thomas Münzel
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

5.  Nitroxyl and its anion in aqueous solutions: spin states, protic equilibria, and reactivities toward oxygen and nitric oxide.

Authors:  Vladimir Shafirovich; Sergei V Lymar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 6.  Endothelin, nitric oxide, and reactive oxygen species in diabetic kidney disease.

Authors:  Jennifer S Pollock; David M Pollock
Journal:  Contrib Nephrol       Date:  2011-08-30       Impact factor: 1.580

7.  Increased superoxide production in nitrate tolerance is associated with NAD(P)H oxidase and aldehyde dehydrogenase 2 downregulation.

Authors:  Katalin Szöcs; Bernard Lassègue; Philip Wenzel; Maria Wendt; Andreas Daiber; Matthias Oelze; Thomas Meinertz; Thomas Münzel; Stephan Baldus
Journal:  J Mol Cell Cardiol       Date:  2007-03-30       Impact factor: 5.000

8.  Peroxynitrite-induced relaxation in isolated canine cerebral arteries and mechanisms of action.

Authors:  Jianfeng Li; Wenyan Li; Bella T Altura; Burton M Altura
Journal:  Toxicol Appl Pharmacol       Date:  2004-04-01       Impact factor: 4.219

9.  Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance.

Authors:  T Münzel; H Sayegh; B A Freeman; M M Tarpey; D G Harrison
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

Review 10.  Nitroxyl (HNO): the Cinderella of the nitric oxide story.

Authors:  Jennifer C Irvine; Rebecca H Ritchie; Joanne L Favaloro; Karen L Andrews; Robert E Widdop; Barbara K Kemp-Harper
Journal:  Trends Pharmacol Sci       Date:  2008-10-01       Impact factor: 14.819

View more
  2 in total

1.  The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation.

Authors:  Sebastian Steven; Matthias Oelze; Michael Hausding; Siyer Roohani; Fatemeh Kashani; Swenja Kröller-Schön; Johanna Helmstädter; Thomas Jansen; Christine Baum; Marc Iglarz; Eberhard Schulz; Thomas Münzel; Andreas Daiber
Journal:  Oxid Med Cell Longev       Date:  2018-12-27       Impact factor: 6.543

2.  Induction of caveolin-3/eNOS complex by nitroxyl (HNO) ameliorates diabetic cardiomyopathy.

Authors:  Hai-Jian Sun; Si-Ping Xiong; Zhi-Yuan Wu; Lei Cao; Meng-Yuan Zhu; Philip K Moore; Jin-Song Bian
Journal:  Redox Biol       Date:  2020-03-05       Impact factor: 11.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.